Natco Pharma faced a USFDA inspection, received seven Form‑483 observations, and pledged swift corrective actions immediately.

• Inspection occurred from 9 June to 19 June 2025, covering manufacturing and quality systems thoroughly.
• Company confidence rests on addressing observations within the regulatory timeline, ensuring continued cGMP compliance with worldwide standards.
• Natco remains committed to supplying high‑quality generic, branded drugs, APIs, and crop protection products globally.